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Introduction
The 2nd annual national ABCD Insulin Pump
Network UK (IPN-UK) meeting took place in
the magnificent iconic venue of Titanic
Belfast. With the famous Titanic ballroom
staircase in the background to set the scene,
Dr Emma Wilmot, Chair of IPN-UK, opened
the meeting with an overview of the success
of the IPN-UK over the previous year. This was
followed by an update from the centre from
Dr Partha Kar, National Associate Clinical Di-
rector for diabetes at NHS England. Quality
improvement in type 1 diabetes is one of his
key priorities, and he challenged the audience
to suggest some key metrics which could be
used to measure the quality of insulin pump
services in the future.  
Papers presented at the meeting
A key recurring topic mentioned by Dr Kar
and also Dr Peter Hammond and Dr Nick
Oliver was the REPOSE trial.1 As readers will
be aware, the REPOSE trial was recently pub-
lished in the BMJ. The main aim of the study
was to answer the questions ‘Are pumps for
all?’. The short answer is no. A group of pa-
tients who did not meet the TA151 guidance
for insulin pump therapy were randomised to
dose adjusted for normal eating (DAFNE) and
multiple daily injections (MDI) or DAFNE and
an insulin pump. Overall there was an im-
provement in HbA1c and severe hypogly-
caemia in both arms, but insulin pump
therapy did not result in a significant reduc-
tion in HbA1c compared with the MDI arm.
The general consensus among the experts re-
garding the REPOSE study was that it should
be taken in context, given that the study pop-
ulation would not have been eligible for in-
sulin pump therapy as per NICE TA151
guidance. The study has highlighted the im-
portance of structured education, its role in
increasing the effectiveness of self-manage-
ment and that MDI therapy is a perfectly
reasonable option for glycaemic control.
Although blanket adoption of insulin pump
therapy is not advocated, its role is still impor-
tant in subgroups of patients – for example,
those meeting the NICE criteria. Unfortu-
nately, as discussed by the IPN committee in
the same issue of this journal, the REPOSE
study has been misinterpreted by some. Dr
Kar reassured healthcare professionals and
patient groups about the implications of the
REPOSE study. Insulin pump therapy access
will continue as per the NICE TA151 guide-
lines and the IPN-UK committee will release a
statement to this effect.   
Dr Bob Young, Lead for the National In-
sulin Pump Audit, detailed the 2016 National
Insulin Pump Audit (NIPA) results such as the
varied use of continuous subcutaneous insulin
infusion (CSII) across centres from 5% to
>50% of patients with type 1 diabetes. He
also highlighted the fact that type 1 diabetes
pump users were more likely to achieve their
treatment targets and achieve a lower HbA1c
than those not using CSII. Delegates discussed
possibilities for improved reporting and
recording of hypoglycaemia and standardising
clinic templates to capture relevant data. Dr
Young highlighted the fact that an increased
number of participating centres resulted in
improved data quality from 2015 NIPA. The
audit team is also keen to improve data qual-
ity and participation in subsequent years. It is
anticipated that the 2018 audit will include a
service level audit for both insulin pump ther-
apy and type 1 diabetes care in general.
Peter Hammond updated delegates on
the latest developments in diabetes technolo-
gies, with insight into the new insulin pumps
including the Kaelido insulin pump,
Medtronic 670G and Medtrum semi-closed
loop. He mentioned that the evidence for
insulin pump use in type 2 diabetes was
developing and presented the OpT2mise
study extension. 
Vey relevant to our clinical practice, there
are some interesting studies on infusion set
changes. Infusion sets should be changed
every 3 days to minimise the risk of occlusion
and/or hyperglycaemia, except in pregnancy
when it is advised that sets are changed every
2 days.2
Professor Nick Oliver from Imperial Col-
lege London then explored evidence relating
to an interesting question becoming very rel-
evant to current practice: ‘Which technology
should come first when intensifying type 1
diabetes management: CSII or continuous
glucose monitoring (CGM)?’ CGM has a pos-
itive impact on HbA1c, time in range and hy-
poglycaemia reduction, regardless of insulin
delivery modality. However, the persistence of
HbA1c drop with CGM is dose-dependent (i.e.
how continuously the sensors are used).
Although the use of both pumps and CGM
has a positive influence on avoiding hypogly-
caemia, CGM is likely to be the better option
for people with hypoglycaemic unawareness
who rely on alarms to alert them to impend-
ing hypoglycaemia.   
Case studies 
Three clinical conundrums submitted by del-
egates underwent detailed analysis by an
IPN-UK expert panel (Dr Pratik Choudhary,
Dr Peter Hammond and Mrs Geraldine
Gallen) with lively discussions among the
delegates. Numerous suggestions for opti-
mising CSII and CGM were raised. It was
stressed that it is important that we use
downloads routinely in the clinic settings
and know how to interpret them. Cases
were reviewed and a number of observa-
tions made. Hyperglycaemia can often be a
late response following hypoglycaemia cor-
rection and many of the hypoglycaemias
occur after a correction dose if the insulin
sensitivity factor is too aggressive. Master-
ing the skills of interpreting CSII and CGM
downloads and adjusting settings are essen-
tial to providing quality diabetes care. The
importance of screening for diabetic distress
was also highlighted. 
Workshops 
There were three interactive workshops
which gave excellent practical tips on prob-
lematic hypoglycaemia, exercise and use of
the Freestyle Libre.
Dr Pratik Choudhary, leading the hypo-
glycaemia workshop, made a very interest-
ing and thought-provoking observation.
Although we do the screening for nephropa-
thy with an incidence of 15–40% and even
thyroid with an even lesser incidence, we do
not routinely screen for significant hypogly-
caemia and hypoglycaemic awareness, which
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has a prevalence of more than 50% in patients
with longstanding diabetes.3 It is very impor-
tant we use validated questionnaires like the
Gold score to detect and quantify hypogly-
caemic awareness.4,5 For persistent hypogly-
caemia, in addition to common causes like
renal failure, gastroparesis and adrenal insuffi-
ciency, look for unpredictable insulin action
(like lipodystrophy and insulin antibodies),
other endocrine abnormalities such as growth
hormone deficiency and mismatch of insulin
need and requirement.
The exercise workshop led by Dr Alistair
Lamb gave an in-depth understanding of
exercise physiology and practices in type 1
diabetes which included the following points:
• Fear of hypoglycaemia is the most impor-
tant factor preventing people from em-
bracing a more active lifestyle.
• If the pre-exercise glucose is higher, it is
ideal to start with aerobic exercise which
will reduce glucose followed by anaerobic
exercise which tends to raise glucose. If the
pre exercise glucose is on the lower side, it
would be a good idea to start with anaer-
obic exercise which will tend to increase
the glucose.
• After prolonged severe hypoglycaemia,
avoid exercise and take more carbohy-
drates.
A highlight of the afternoon was an insight-
ful session from international guest speaker
and founder of ‘Sugar Surfing’, Dr Steven
Ponder, a paediatrician from Texas who was
diagnosed with type 1 diabetes at a young
age.6 He is driven by a passion to revolu-
tionise glycaemic management and give all
the necessary tools to patients and their fam-
ilies to allow them to make appropriate de-
cisions. He gave a fascinating insight into the
decision skills and matrix for ‘microbolusing’
and ‘microcarbing’ both reactively and pro-
actively to achieve very little glycaemic vari-
ability in order to obtain a tight HbA1c (even
less than 6%) without hypoglycaemia. He
describes his tool as ‘cranial pancreas’. It
needs a lot of dedication and commitment.
It might not be every patient’s cup of tea, but
could be an option for the most dedicated
few. He is offering to give the electronic ver-
sion free for newly diagnosed patients with
type 1 diabetes (www.sugarsurfing.com or
the book ‘Sugar surfing: How to manage
type 1 diabetes in a modern world’) to all
members of the IPN-UK. 
In addition to the technical aspects of dia-
betes self-care, he gave us an insight into the
psychology of success and some very pertinent
tips. The importance of avoiding use of the ter-
minologies ‘good’ and ‘bad’ with glucose lev-
els has huge significance. It is important not to
judge and to use alternative terminologies like
high/low/in range instead. It is so crucial that
we as healthcare professionals reward the
effort and not the results and give patients a
goal for normal life. HbA1c and glucose are
only a means to an end. This dialogue and
non-judgemental approach should be the
norm for routine care of patients with type 1
patients from the point of diagnosis. 
The whole day was thoroughly enjoyable
and superbly paced, and it was not until the
end of the meeting that we were fully able to
appreciate the grandeur of the venue. Titanic
Belfast is certainly worth a visit if you have a
weekend to spare. We look forward to another
exciting and informative meeting next year.
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